Elizabeth H.Z. Thompson, Executive Vice President, Head of Research and Development at Acadia Pharmaceuticals Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Elizabeth H.Z. Thompson, Ph.D., has served as ACADIA's Executive Vice President, Head of Research and Development since April 2024, leading the company's neuroscience and rare-disease R&D organization; in April 2026 she announced her intention to retire by the end of the year. Before joining ACADIA she was Executive Vice President, Research and Development (Rare Disease) at Amgen following its acquisition of Horizon Therapeutics, where she had served as Executive Vice President, Research and Development. Earlier she held clinical-development leadership roles at AbbVie (clinical lead for risankizumab/SKYRIZI), Raptor Pharmaceuticals, InterMune and Amgen. She earned a B.S. in chemistry from Harvey Mudd College and a Ph.D. in macromolecular and cellular structure and chemistry from The Scripps Research Institute.
Roles
Acadia Pharmaceuticals Inc.
Executive Vice President, Head of Research and Development · Current role
April 2024–present
ACADIA Pharmaceuticals
Executive Vice President, Head of Research and Development · announced intention to retire by year-end 2026
April 2024 - present
Amgen Inc.
Executive Vice President, Research and Development (Rare Disease)
October 2023 - January 2024
Horizon Therapeutics plc
Executive Vice President, Research and Development
March 2021 - October 2023
Horizon Therapeutics plc
Group Vice President, Development and External Search
January 2020 - March 2021
Horizon Therapeutics plc
Vice President, Clinical Development (Rare Disease)
June 2018 - January 2020
AbbVie Inc.
Group Scientific Director / Senior Scientific Director, Clinical Development
September 2015 - May 2018
External Roles
IGM Biosciences, Inc.
Director
until August 2025
Fixed Compensation
FY 2025
Salary
$647,325
ComponentAnnual base salary earned in FY2025
All other compensation
$19,217
Component401(k) match, insurance premiums, and other perquisites
Total compensation
$2,888,383
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$372,272
Target Opportunity
—
PlanAnnual cash bonus under the corporate incentive plan